INDUSTRY NEWS

FDA Approves Dapagliflozin for CKD Patients

The US Food and Drug Administration has approved dapagliflozin (Farxiga; AstraZeneca) to reduce the risk of renal and cardiovascular adverse events in patients with chronic kidney disease (CKD) who are at risk of disease progression, irrespective of whether they have diabetes.

Rural-Urban Disparities: Diabetes, Hypertension, Heart Disease, and Stroke Mortality Among Black and White Adults
Co-authored by Eméfah C. Loccoh (with Rahul Aggarwal, Nicholas Chiu, Dhruv S. Kazi, Robert W. Yeh, and Rishi K. Wadhera)

With minimal improvement across the past 2 decades, racial disparities between Black and White patients continue to be widest with regards to mortality rates for diabetes and hypertension (HTN), with Black adults 2 to 3 times more likely to die from complications compared with their White counterparts. Ms. Loccoh was the recipient of the 2020 Dr. Richard Allen Williams & Genita Evangelista Johnson/ABC Scholarship and will start her...

The Association of Structural Inequities and Race with out-of-Hospital Sudden Death during the COVID-19 Pandemic
Co-authored by Jennifer H. Mieres and Robert O. Roswell (with Stavros E. Mountantonakis, Laurence M. Epstein, Kristie Coleman, Johanna Martinez, Moussa Saleh, Charlotte Kvasnovsky, Rachel-Maria Brown, et al.)

Social influencers of health (SIOH) namely race, ethnicity and structural inequities are known to affect the incidence of out of hospital sudden death (OHSD). We sought to examine the association between SIOH and the incidence of OHSD in the diverse neighborhoods of New York City (NYC) during the first wave of COVID-19 epidemic.

ADDITIONAL UPDATES

Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System
Co-authored by Tochi M. Okwuosa (with Alicia Morgans, June-Wha Rhee, Kerryn W. Reding, Sally Maliski, Juan-Carlos Plana, Annabelle Santos Volgman, Kendall F. Moseley, Charles B. Porter and Roohi Ismail-Khan)

Cardiovascular disease and cancer are the leading causes of death in the United States, and hormone-dependent cancers (breast and prostate cancer) are the most common noncutaneous malignancies in women and men, respectively. The hormonal (endocrine-related) therapies that serve as a backbone for treatment of both cancers improve survival but also increase cardiovascular morbidity and mortality among survivors.

Cath Lab Team 'Not Off the Hook' for Racial Disparities in Medicine

Interventional cardiologists have as much a part to play in eliminating decades-old racial disparities in cardiovascular care as their colleagues and stakeholders, Quinn Capers IV, MD, of UT Southwestern Medical Center in Dallas, suggested during his Hildner Lecture at this year's virtual scientific sessions of the Society for Cardiovascular Angiography and Interventions (SCAI).

Washington, District of Columbia
email: cmccullough@abcardio.org
Phone: 800-753-9222

Subscribe to ABC Clinical Updates & Insights

*Email:
*First Name:
*Last Name:
*Company:
Title:
Street Address:
City:
State / Province:
Zip / Postal Code:
Country:
Privacy Policy